Skip to main content
Erschienen in: Breast Cancer 2/2010

01.04.2010 | Case Report

A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II

verfasst von: Naoki Hino, Yasusi Nakagawa, Youko Ikushima, Mitsuteru Yoshida, Masaru Tsuyuguchi

Erschienen in: Breast Cancer | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

We report the case of a patient who presented with hypoglycemia associated with a giant breast mass and presence of serum high-molecular-weight insulin-like growth factor II (big IGF-II). In July 2005, a 49-year-old woman was admitted because of delirium, transient loss of consciousness, and a giant mass of about 28 cm in diameter on the right breast. She had noticed the mass for more than 2 years, but had refused medical attention at that time. A blood examination indicated hypoglycemia (21 mg/dl) and decreased levels of endogenous insulin. Furthermore, a western blot analysis revealed that big IGF-II (20 kDa) was the predominant serum IGF-II peptide (mature IGF-II is 7.5 kDa). Because we suspected that the big IGF-II was produced by the breast tumor and was likely the cause of the hypoglycemia, a mastectomy was performed. A histological examination determined that the mass was a benign phyllodes tumor. After surgery, the hypoglycemia resolved, and endogenous insulin levels improved. We suspected that the patient had non-islet cell tumor hypoglycemia (NICTH), but the behavioral symptoms of the hypoglycemia caused by NICTH were similar to some mental diseases, which made diagnosis based on the behavior alone difficult. We suggest that co-occurrence of symptoms such as recent appearance of mental disease-like behavior, hypoglycemia, and giant breast tumor may help diagnose NICTH caused by big IGF-II.
Literatur
1.
Zurück zum Zitat Liu F, Baker BK, Powell DR, Hintz RL. Characterization of proinsulin-like growth factor-II E-region immunoreactivity in serum and other biological fluids. J Clin Endocrinol Metab. 1993;76:1095–100.CrossRefPubMed Liu F, Baker BK, Powell DR, Hintz RL. Characterization of proinsulin-like growth factor-II E-region immunoreactivity in serum and other biological fluids. J Clin Endocrinol Metab. 1993;76:1095–100.CrossRefPubMed
2.
Zurück zum Zitat Hizuka N, Fukuda I, Takano K, Asakawa-Yasumoto K, Okubo Y, Demura H. Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated. J Clin Endocrinol Metab. 1998;83:2875–7.CrossRefPubMed Hizuka N, Fukuda I, Takano K, Asakawa-Yasumoto K, Okubo Y, Demura H. Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated. J Clin Endocrinol Metab. 1998;83:2875–7.CrossRefPubMed
3.
Zurück zum Zitat Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab. 1991;73:696–702.CrossRefPubMed Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab. 1991;73:696–702.CrossRefPubMed
4.
Zurück zum Zitat Zapf J, Futo E, Peter M, Froesch ER. Can “big” insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest. 1992;90:2574–84.CrossRefPubMed Zapf J, Futo E, Peter M, Froesch ER. Can “big” insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest. 1992;90:2574–84.CrossRefPubMed
5.
Zurück zum Zitat Bourcigaux N, Arnault-Ouary G, Christol R, Perin L, Charbonnel B, Le Bouc Y. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clin Ther. 2005;27:246–51.CrossRefPubMed Bourcigaux N, Arnault-Ouary G, Christol R, Perin L, Charbonnel B, Le Bouc Y. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clin Ther. 2005;27:246–51.CrossRefPubMed
6.
Zurück zum Zitat Phillips LS, Robertson DG. Insulin-like growth factors and non-islet cell tumor hypoglycemia. Metabolism. 1993;42:1093–101.CrossRefPubMed Phillips LS, Robertson DG. Insulin-like growth factors and non-islet cell tumor hypoglycemia. Metabolism. 1993;42:1093–101.CrossRefPubMed
7.
Zurück zum Zitat Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res. 2006;16:211–6.CrossRefPubMed Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res. 2006;16:211–6.CrossRefPubMed
8.
Zurück zum Zitat Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;319:1434–40.PubMed Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;319:1434–40.PubMed
9.
Zurück zum Zitat Hizuka N, Fukuda I, Takano K, Okubo Y, Asakawa-Yasumoto K, Demura H. Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J. 1998;45(Suppl):S61–5.CrossRefPubMed Hizuka N, Fukuda I, Takano K, Okubo Y, Asakawa-Yasumoto K, Demura H. Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J. 1998;45(Suppl):S61–5.CrossRefPubMed
10.
Zurück zum Zitat Gorden P, Hendricks CM, Kahn CR, Megyesi K, Roth J. Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. N Engl J Med. 1981;305:1452–5.PubMedCrossRef Gorden P, Hendricks CM, Kahn CR, Megyesi K, Roth J. Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. N Engl J Med. 1981;305:1452–5.PubMedCrossRef
11.
Zurück zum Zitat Li TC, Reed CE, Stubenbord WT Jr, Ettinghausen S, Peterson CM, Jovanovic L, et al. Surgical cure of hypoglycemia associated with cystosarcoma phyllodes and elevated nonsuppressible insulin-like protein. Am J Med. 1983;74:1080–4.CrossRefPubMed Li TC, Reed CE, Stubenbord WT Jr, Ettinghausen S, Peterson CM, Jovanovic L, et al. Surgical cure of hypoglycemia associated with cystosarcoma phyllodes and elevated nonsuppressible insulin-like protein. Am J Med. 1983;74:1080–4.CrossRefPubMed
12.
Zurück zum Zitat Kataoka T, Haruta R, Goto T, Sugino K, Asahara T, Dohi K, et al. Malignant phyllodes tumor of the breast with hypoglycemia: report of a case. Jpn J Clin Oncol. 1998;28:276–80.CrossRefPubMed Kataoka T, Haruta R, Goto T, Sugino K, Asahara T, Dohi K, et al. Malignant phyllodes tumor of the breast with hypoglycemia: report of a case. Jpn J Clin Oncol. 1998;28:276–80.CrossRefPubMed
13.
Zurück zum Zitat Aguiar Bujanda D, Rivero Vera JC, Cabrera Suarez MA, Aguiar Morales J, Christol R, Bohn Sarmiento U, et al. Hypoglycemic coma secondary to big insulin-like growth factor II secretion by a giant phyllodes tumor of the breast. Breast J. 2007;13:189–91.CrossRefPubMed Aguiar Bujanda D, Rivero Vera JC, Cabrera Suarez MA, Aguiar Morales J, Christol R, Bohn Sarmiento U, et al. Hypoglycemic coma secondary to big insulin-like growth factor II secretion by a giant phyllodes tumor of the breast. Breast J. 2007;13:189–91.CrossRefPubMed
Metadaten
Titel
A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II
verfasst von
Naoki Hino
Yasusi Nakagawa
Youko Ikushima
Mitsuteru Yoshida
Masaru Tsuyuguchi
Publikationsdatum
01.04.2010
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 2/2010
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0094-z

Weitere Artikel der Ausgabe 2/2010

Breast Cancer 2/2010 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.